Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI IBD Plus
- Development stage
- Unknown
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
AVI IBD Plus is a live-attenuated, freeze-dried veterinary vaccine developed by Laprovet (a Ceva Santé Animale company) and marketed by Navana Pharmaceuticals. It contains the live-attenuated Winterfield 2512 G-61 strain of the Infectious Bursal Disease virus (IBDV). The vaccine is indicated for the active immunization of healthy poultry, including broilers and pullets, against Infectious Bursal Disease (also known as Gumboro disease), particularly cases caused by very virulent strains. It is typically administered orally via drinking water.
- Brand names
- AVI IBD Plus
- Other names
- Gumboro disease vaccineInfectious bursal disease vaccineInfectious bursal disease vaccine (Winterfield 2512 G-61 strain)Infectious bursal disease virus vaccineInfectious bursal disease virus vaccine (Winterfield 2512 G-61 strain)
Beyond the preview
Go deeper on AVI IBD Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI IBD Plus.